These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 2425046)

  • 1. Antigenic structure of polioviruses of serotypes 1, 2 and 3.
    Minor PD; Ferguson M; Evans DM; Almond JW; Icenogle JP
    J Gen Virol; 1986 Jul; 67 ( Pt 7)():1283-91. PubMed ID: 2425046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Principal and subsidiary antigenic sites of VP1 involved in the neutralization of poliovirus type 3.
    Minor PD; Evans DM; Ferguson M; Schild GC; Westrop G; Almond JW
    J Gen Virol; 1985 May; 66 ( Pt 5)():1159-65. PubMed ID: 2582084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamics of Evolution of Poliovirus Neutralizing Antigenic Sites and Other Capsid Functional Domains during a Large and Prolonged Outbreak.
    Shaw J; Jorba J; Zhao K; Iber J; Chen Q; Adu F; Adeniji A; Bukbuk D; Baba M; Henderson E; Dybdahl-Sissoko N; McDonald S; Weldon WC; Gumede N; Oberste MS; Kew OM; Burns CC
    J Virol; 2018 May; 92(9):. PubMed ID: 29444940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations conferring resistance to neutralization with monoclonal antibodies in type 1 poliovirus can be located outside or inside the antibody-binding site.
    Blondel B; Crainic R; Fichot O; Dufraisse G; Candrea A; Diamond D; Girard M; Horaud F
    J Virol; 1986 Jan; 57(1):81-90. PubMed ID: 2416957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of monoclonal antibodies for the identification of the antigenic site for poliovirus neutralization.
    Minor PD; Schild GC; Evans D; Ferguson M; Almond J
    Dev Biol Stand; 1984; 57():171-5. PubMed ID: 6084608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of a monoclonal antibody and of DNA recombinant technology for the localization of a poliovirus neutralization epitope in viral capsid polypeptide VP1.
    Bruneau P; van der Werf S; Wychowski C; Siffert O; Girard M
    Dev Biol Stand; 1984; 57():177-85. PubMed ID: 6084609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antigenic sites of poliovirus type 3 eliciting IgA monoclonal antibodies in orally immunized mice.
    Buttinelli G; Ruggeri FM; Marturano J; Novello F; Donati V; Fiore L
    Virology; 2001 Mar; 281(2):265-71. PubMed ID: 11277698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antigenic sites on type 2 poliovirus.
    Patel V; Ferguson M; Minor PD
    Virology; 1993 Jan; 192(1):361-4. PubMed ID: 7685967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Poliovirus Sabin type 1 neutralization epitopes recognized by immunoglobulin A monoclonal antibodies.
    Fiore L; Ridolfi B; Genovese D; Buttinelli G; Lucioli S; Lahm A; Ruggeri FM
    J Virol; 1997 Sep; 71(9):6905-12. PubMed ID: 9261417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolution of poliovirus during an outbreak: sequential type 3 poliovirus isolates from several persons show shifts of neutralization determinants.
    Huovilainen A; Hovi T; Kinnunen L; Takkinen K; Ferguson M; Minor P
    J Gen Virol; 1987 May; 68 ( Pt 5)():1373-8. PubMed ID: 2437244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of the location of antigenic sites of swine vesicular disease virus with neutralization-resistant mutants.
    Kanno T; Inoue T; Wang Y; Sarai A; Yamaguchi S
    J Gen Virol; 1995 Dec; 76 ( Pt 12)():3099-106. PubMed ID: 8847515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antigenic analysis of poliovirus type 3 using monoclonal antibodies.
    Ferguson M; Minor PD; Magrath DI; Schild GC
    Dev Biol Stand; 1984; 57():151-5. PubMed ID: 6098495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunochemical studies of polioviruses: identification of immunoreactive virus capsid polypeptides.
    Thorpe R; Minor PD; Mackay A; Schild GC; Spitz M
    J Gen Virol; 1982 Dec; 63(2):487-92. PubMed ID: 6185628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antigenic structure of chimeras of type 1 and type 3 polioviruses involving antigenic sites 2, 3 and 4.
    Minor PD; Ferguson M; Katrak K; Wood D; John A; Howlett J; Dunn G; Burke K; Almond JW
    J Gen Virol; 1991 Oct; 72 ( Pt 10)():2475-81. PubMed ID: 1717641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of residues in VP2 that contribute to poliovirus neutralization antigenic site 3B.
    Reynolds C; Page G; Zhou H; Chow M
    Virology; 1991 Sep; 184(1):391-6. PubMed ID: 1714663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Studies of the antigenic variation in poliovirus type 1. Selection and analysis of variant strains with monoclonal antibodies by neutralization.
    Thibodeau L; Lacroix M; Lecomte J; Fauvel M
    Dev Biol Stand; 1984; 57():157-63. PubMed ID: 6084606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of a recombinant type 3/type 2 poliovirus isolated from a healthy vaccinee and containing a chimeric capsid protein VP1.
    Blomqvist S; Bruu AL; Stenvik M; Hovi T
    J Gen Virol; 2003 Mar; 84(Pt 3):573-580. PubMed ID: 12604808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mapping of type 1 poliovirus neutralization epitopes.
    Blondel B; Crainic R; Dufraisse G; Candréa A; Horaud F
    Dev Biol Stand; 1985; 60():337-42. PubMed ID: 2412917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Binding of neutralizing monoclonal antibodies to empty capsids of poliovirus can be blocked by monospecific antisera to structural polypeptides VP1 and VP2.
    Uhlig H; Haardt F; Dernick R
    Arch Virol; 1985; 83(3-4):295-303. PubMed ID: 2578787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cleavage of VP1 and modification of antigenic site 1 of type 2 polioviruses by intestinal trypsin.
    Roivainen M; Hovi T
    J Virol; 1988 Sep; 62(9):3536-9. PubMed ID: 2841503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.